Immunophenotype and clonally rearranged TCR alleles in CALM-AF10 T-ALLs compared to negative cases with a similar stage of maturation arrest
. | IM TCR-/cTCRβ- (%) . | . | . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
. | IMO . | IMδ/IMγ . | . | IMβ . | αβ lineage: TCRαβ and TCR+/cTCRβ+ (%) . | TCRγδ (%) . | . | |||
| CALM-AF10 | 0/5 | 12/29 | 0/12 | 0/66 | 8/32 | |||||
| CALM-AF10+ | CALM-AF10- | CALM-AF10+ | CALM-AF10- | |||||||
| Mean age, y | 38.4 | 24.3 | 28.6 | 15.1 | 21.8 | 17.8 | 20.1 | |||
| Children/adults | 1/4 | 3/9 | 1/16 | 7/5 | 26/40 | 5/3 | 13/11 | |||
| Immunophenotype | ||||||||||
| CD34 | 5/5 (100) | 6/12 (50) | 8/16 (50) | 9/12 (75) | 12/65 (18) | 1/7 (14) | 7/24 (29) | |||
| CD117 | 1/5 (20) | 1/10 (10) | 2/14 (14) | 1/11 (9) | 0/57 (0) | 1/7 (14) | 2/18 (11) | |||
| CD13/33 | 4/5 (80) | 5/12 (42) | 7/16 (44) | 3/12 (25) | 3/62 (5) | 1/8 (13) | 7/23 (30) | |||
| CD56 | 1/5 (20) | 0/9 (0)* | 6/14 (43) | 4/10 (40) | 0/43 (0) | 1/6 (17) | 0/17 (0) | |||
| CD5 | 3/5 (60) | 8/12 (67) | 14/17 (82) | 12/12 (100) | 65/66 (98) | 7/8 (88) | 24/24 (100) | |||
| CD2 | 4/5 (80) | 1/12 (8)† | 12/17 (71) | 7/12 (58) | 61/66 (92) | 3/8 (38) | 11/24 (46) | |||
| CD5+/CD2- | 1/5 (20) | 7/12 (58)* | 3/17 (18) | 7/12 (58) | 5/66 (7) | 4/8 (50) | 13/24 (54) | |||
| CD4/8 DN | 5/5 (100) | 10/12 (83) | 15/17 (88) | 4/12 (33) | 6/66 (9) | 1/8 (13) | 11/23 (48) | |||
| CD4 SP | 0/5 (0) | 2/12 (17) | 1/17 (6) | 3/12 (25) | 8/66 (12) | 2/8 (25) | 4/23 (17) | |||
| CD8 SP | 0/5 (0) | 0/12 (0) | 1/17 (6) | 1/12 (8) | 7/66 (11) | 2/8 (25) | 3/23 (13) | |||
| CD4/8 DP | 0/5 (0) | 0/12 (0) | 0/17 (0) | 4/12 (33) | 45/66 (68) | 3/8 (38) | 5/23 (22) | |||
| CD1a | 2/5 (20) | 3/11 (27) | 2/17 (12) | 6/11 (55) | 47/66 (71) | 2/8 (25) | 5/24 (21) | |||
| CD10 | 0/5 (0) | 2/11 (18) | 2/15 (13) | 9/12 (75) | 23/65 (35) | 2/8 (25) | 10/24 (42) | |||
| TdT | 5/5 (100) | 6/10 (60) | 9/13 (69) | 10/11 (91) | 51/57 (90) | 3/5 (60) | 10/14 (71) | |||
| Clonal rearranged TCRδ and TCRγ alleles | ||||||||||
| Vδ2-Dδ3/Dδ2-Dδ3 | 5/21 (24) | 17/28 (61) | 1/14 (7) | 1/34 (3) | 1/13 (8) | 1/29 (3) | ||||
| Dδ2-Jδ1 | 11/21 (52) | 8/28 (29) | 4/14 (29) | 4/34 (12) | 1/13 (8) | 2/29 (7) | ||||
| TCRδ V(D)J | 5/21 (24) | 3/28 (10) | 9/14 (64) | 29/34 (85) | 11/13 (84) | 26/29 (90) | ||||
| TCRγ Vf1/V9 | 10/14 (71) | 8/15 (53) | 20/24 (83) | 99/116 (85) | 12/14 (86) | 27/35 (77) | ||||
| TCRγ V10/V11 | 4/14 (29) | 7/15 (47) | 4/24 (17) | 17/116 (15) | 2/14 (14) | 8/35 (23) | ||||
. | IM TCR-/cTCRβ- (%) . | . | . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
. | IMO . | IMδ/IMγ . | . | IMβ . | αβ lineage: TCRαβ and TCR+/cTCRβ+ (%) . | TCRγδ (%) . | . | |||
| CALM-AF10 | 0/5 | 12/29 | 0/12 | 0/66 | 8/32 | |||||
| CALM-AF10+ | CALM-AF10- | CALM-AF10+ | CALM-AF10- | |||||||
| Mean age, y | 38.4 | 24.3 | 28.6 | 15.1 | 21.8 | 17.8 | 20.1 | |||
| Children/adults | 1/4 | 3/9 | 1/16 | 7/5 | 26/40 | 5/3 | 13/11 | |||
| Immunophenotype | ||||||||||
| CD34 | 5/5 (100) | 6/12 (50) | 8/16 (50) | 9/12 (75) | 12/65 (18) | 1/7 (14) | 7/24 (29) | |||
| CD117 | 1/5 (20) | 1/10 (10) | 2/14 (14) | 1/11 (9) | 0/57 (0) | 1/7 (14) | 2/18 (11) | |||
| CD13/33 | 4/5 (80) | 5/12 (42) | 7/16 (44) | 3/12 (25) | 3/62 (5) | 1/8 (13) | 7/23 (30) | |||
| CD56 | 1/5 (20) | 0/9 (0)* | 6/14 (43) | 4/10 (40) | 0/43 (0) | 1/6 (17) | 0/17 (0) | |||
| CD5 | 3/5 (60) | 8/12 (67) | 14/17 (82) | 12/12 (100) | 65/66 (98) | 7/8 (88) | 24/24 (100) | |||
| CD2 | 4/5 (80) | 1/12 (8)† | 12/17 (71) | 7/12 (58) | 61/66 (92) | 3/8 (38) | 11/24 (46) | |||
| CD5+/CD2- | 1/5 (20) | 7/12 (58)* | 3/17 (18) | 7/12 (58) | 5/66 (7) | 4/8 (50) | 13/24 (54) | |||
| CD4/8 DN | 5/5 (100) | 10/12 (83) | 15/17 (88) | 4/12 (33) | 6/66 (9) | 1/8 (13) | 11/23 (48) | |||
| CD4 SP | 0/5 (0) | 2/12 (17) | 1/17 (6) | 3/12 (25) | 8/66 (12) | 2/8 (25) | 4/23 (17) | |||
| CD8 SP | 0/5 (0) | 0/12 (0) | 1/17 (6) | 1/12 (8) | 7/66 (11) | 2/8 (25) | 3/23 (13) | |||
| CD4/8 DP | 0/5 (0) | 0/12 (0) | 0/17 (0) | 4/12 (33) | 45/66 (68) | 3/8 (38) | 5/23 (22) | |||
| CD1a | 2/5 (20) | 3/11 (27) | 2/17 (12) | 6/11 (55) | 47/66 (71) | 2/8 (25) | 5/24 (21) | |||
| CD10 | 0/5 (0) | 2/11 (18) | 2/15 (13) | 9/12 (75) | 23/65 (35) | 2/8 (25) | 10/24 (42) | |||
| TdT | 5/5 (100) | 6/10 (60) | 9/13 (69) | 10/11 (91) | 51/57 (90) | 3/5 (60) | 10/14 (71) | |||
| Clonal rearranged TCRδ and TCRγ alleles | ||||||||||
| Vδ2-Dδ3/Dδ2-Dδ3 | 5/21 (24) | 17/28 (61) | 1/14 (7) | 1/34 (3) | 1/13 (8) | 1/29 (3) | ||||
| Dδ2-Jδ1 | 11/21 (52) | 8/28 (29) | 4/14 (29) | 4/34 (12) | 1/13 (8) | 2/29 (7) | ||||
| TCRδ V(D)J | 5/21 (24) | 3/28 (10) | 9/14 (64) | 29/34 (85) | 11/13 (84) | 26/29 (90) | ||||
| TCRγ Vf1/V9 | 10/14 (71) | 8/15 (53) | 20/24 (83) | 99/116 (85) | 12/14 (86) | 27/35 (77) | ||||
| TCRγ V10/V11 | 4/14 (29) | 7/15 (47) | 4/24 (17) | 17/116 (15) | 2/14 (14) | 8/35 (23) | ||||
Both the consecutive series of 131 and the 13 selected cases are included. No significant differences in immunophenotype were seen in TCRγδ T-ALLs. Differences in IM T-ALLs are indicated as *P = .02 or δP = .001. IM T-ALLs are subdivided on the basis of their TCRδ, TCRγ, and TCRβ rearrangements, as detailed in the text and legend to Figure 1
DN indicates double negative; SP, single positive